| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | 1,3-Benzodioxol-5-ol,6-[1-pyrrolidinyl(3,4,5-trimethoxyphenyl)methyl]- Basic information |
| | 1,3-Benzodioxol-5-ol,6-[1-pyrrolidinyl(3,4,5-trimethoxyphenyl)methyl]- Chemical Properties |
| form | Solid | | color | Off-white to light yellow |
| | 1,3-Benzodioxol-5-ol,6-[1-pyrrolidinyl(3,4,5-trimethoxyphenyl)methyl]- Usage And Synthesis |
| Uses | NSC-370284 is a selective inhibitor of ten-eleven translocation 1 (TET1) and 5-hydroxymethylcytosine (5hmC). NSC-370284 significantly inhibits the level of TET1 expression via targets STAT3/5[1]. | | in vivo | NSC-370284 (2.5 mg/kg; i.p., once daily for 10 days) improves the pathological morphologies in peripheral blood (PB), bone marrow (BM), spleen, and liver tissues in MLL-AF9 acute myeloid leukemia (AML) mice model[1]. | Animal Model: | C57BL/6 (CD45.2) and B6.SJL (CD45.1) mice[1]. | | Dosage: | 2.5mg/kg. | | Administration: | Intraperitoneal injection, once daily, for 10 days. | | Result: | Significantly inhibited MLL-AF9 induced AML in secondary bone marrow transplantation (BMT) recipient mice. |
| | IC 50 | STAT3; STAT5; TET1 | | References | [1] Jiang X, et al. Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Nat Commun. 2017 Dec 13;8(1):2099. DOI:10.1038/s41467-017-02290-w |
| | 1,3-Benzodioxol-5-ol,6-[1-pyrrolidinyl(3,4,5-trimethoxyphenyl)methyl]- Preparation Products And Raw materials |
|